| Literature DB >> 29880723 |
Katharina Imkeller1,2, Stephen W Scally3, Alexandre Bosch3, Gemma Pidelaserra Martí1,2, Giulia Costa4, Gianna Triller1, Rajagopal Murugan1, Valerio Renna5, Hassan Jumaa5, Peter G Kremsner6, B Kim Lee Sim7, Stephen L Hoffman7, Benjamin Mordmüller6, Elena A Levashina4, Jean-Philippe Julien8,9, Hedda Wardemann10.
Abstract
Affinity maturation selects B cells expressing somatically mutated antibody variants with improved antigen-binding properties to protect from invading pathogens. We determined the molecular mechanism underlying the clonal selection and affinity maturation of human B cells expressing protective antibodies against the circumsporozoite protein of the malaria parasite Plasmodium falciparum (PfCSP). We show in molecular detail that the repetitive nature of PfCSP facilitates direct homotypic interactions between two PfCSP repeat-bound monoclonal antibodies, thereby improving antigen affinity and B cell activation. These data provide a mechanistic explanation for the strong selection of somatic mutations that mediate homotypic antibody interactions after repeated parasite exposure in humans. Our findings demonstrate a different mode of antigen-mediated affinity maturation to improve antibody responses to PfCSP and presumably other repetitive antigens.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29880723 PMCID: PMC6420115 DOI: 10.1126/science.aar5304
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728
Fig. 1Affinity maturation of high-affinity human PfCSP NANP antibodies. (A) Surface plasmon resonance (SPR) affinity and SHM of selected (labeled) VH3-33–Vκ1-5–KCDR3:8 (green) and non–VH3-33–Vκ1-5–KCDR3:8 (gray) anti-PfCSP antibodies (). (B to D) Original and mutated antibodies. [(B) and (C)] PfCSP enzymelinked immunosorbent assay reactivity. Data in (A), (B), and (C) are from one experiment representative of at least two independent experiments. OD, optical density; Ab, antibody. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr. (D) Pf liver cell traversal inhibition. Bars represent means from two to four independent experiments (symbols represent results from individual experiments). **P = 0.01 (significant) for two-tailed Student’s t test. (E) Silent (gray) and replacement (red) SHM (bars) in VH3-33–Vκ1-5 antibodies (n = 63). FWR, framework region; aa, amino acid. (F) Observed (obs) amino acid usage compared with a baseline (base) model (, ). (G and H) Independent NANP3 SPR affinity measurements (dots) and means (gray lines). **P = 0.01 (significant) for Bonferroni multiple-comparisons test; ns, not significant. KD, equilibrium dissociation constant.
HCDR2 residues encoded by different IGHV3-33, IGHV3-30, IGHV3-30-3, and IGHV3-30-5 alleles. Gene and allele data are from www.imgt.org/genedb/.
| Gene | Allele(s) | Residue at position | |||
|---|---|---|---|---|---|
| 50 | 51 | 52 | 52A | ||
| 01, 02, 03, 04, 06 | V | I | W | Y | |
| 05 | V | I | S | Y | |
| 01, 03, 04, 05, 06, 07, 08, 09, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 | V | I | S | Y | |
| 01, 02, 03 | V | I | S | Y | |
| 01 | V | I | S | Y | |
Fig. 2Affinity maturation drives homotypic repeat binding. (A to H) 1210 Fab-NANP5 cocrystal structure. (A) Superposition of the four NANP-bound Fabs. (B) Surface representation of the antigen-antibody interaction. (C) Details of core epitope recognition by 1210. Black dashes indicate H bonds. (D) Two 1210 Fabs in complex with NANP5. [(E) and (F)] Surface representations of Fab-B (E) and Fab-A (F). Residues involved in homotypic interactions are dark gray. [(G) and (H)] Details of homotypic interactions. Affinitymatured residues are labeled in red. (I) Mean ± SEM KD determined by isothermal titration calorimetry (ITC). Dots represent independent measurements. One-tailed Mann-Whitney test: *P < 0.05, **P < 0.01. (J) Results from size exclusion chromatography coupled with multiangle light scattering (SEC-MALS) for the 1210 Fab–PfCSP complex. The red line indicates mean ± SD molar mass from two measurements. RIU, refractive index units. (K) Two-dimensional class averages for the 1210 Fab–PfCSP complex. Red arrows indicate individual Fabs, and red lines indicate the binding angle observed in the crystal structure (D). NF54, Pf strain. Scale bar, 10 nm.
Fig. 3B cell activation and parasite inhibition. (A to D) NANP5-induced calcium signaling of 1210 and variants. [(A) and (B)] Reaction kinetics and percentages of activated cells (A) and overlay of median signal intensities (B) with 1 mg/ml NANP5 for one of at least six representative experiments. Indo, calcium indicator. [(C) and (D)] Percentages of activated cells and median activation time after the addition of 1 mg/ml (C) (n = 6 or 7 experiments) and 0.1 mg/ml (D) (n = 3 experiments) NANP5. Symbols indicate results from independent experiments, and lines and error bars indicate means ± SD. **P = 0.01 (significant) for Bonferroni multiple-comparisons test. (E and F) Parasite inhibition. (E) Mean ± SD median inhibitory concentration (IC50) values from at least three independent experiments for 1210 and 2163 antibodies with indicated NANP3 affinities.We detected no significant differences between IC50 values because of extensively overlapping confidence intervals. (F) Percentages of parasite-free mice after passive immunization with 30 or 100 mg of 1210 or variants 24 hours before subcutaneous injection with Plasmodium berghei sporozoites expressing PfCSP (Pb-PfCSP). Data are from one (100 mg) or two (30 mg) independent experiments with five mice per group.We detected no significant differences in survival for 1210 variants (Mantel-Cox test).
Fig. 4Antihomotypic affinity maturation in SPR affinity and SHM of 1450 out of all VH3-23–Vκ1-5 (green) and non–VH3-23–Vκ1-5 (gray) anti-PfCSP antibodies (). (B) Silent and replacement SHM (bars) in VH3-23–Vκ1-5 antibodies (n = 100). (C to E) Fab 1450–NANP5 cocrystal structure. Head-to-head binding mode (C), Fab-Fab (D), and Fab-NANP5 (E) interactions. Black dashes indicate H bonds. Affinity-matured residues are colored according to the SHM amino acid usage scheme and are labeled in red. Observed amino acid usage is compared with a baseline model (, ). (F) VH3-33– Vκ1-5–KCDR3:8 or VH3-23–Vκ1-5 antibodies in total memory B cells (), CD19+CD27hiCD38hi plasmablasts (PB), and CD19+CD27+ PfCSP-reactive memory B cells (CSPmem) (, ). Dots represent subsamples of 1500 sequences. Box plots show the median, SD, maximum, and minimum of the distribution. ***P = 0.001 (significant) for two-tailed Student’s t test. (G) Frequency of VH3-33–Vκ1-5– KCDR3:8 and VH3-23–Vκ1-5 antibodies among clonally expanded versus singlet pooled PB and CSPmem ().